{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T03:14:07Z","timestamp":1767237247950,"version":"build-2065373602"},"reference-count":44,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T00:00:00Z","timestamp":1605657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006588","name":"Ministarstvo Znanosti, Obrazovanja i Sporta","doi-asserted-by":"publisher","award":["045-191348-0139"],"award-info":[{"award-number":["045-191348-0139"]}],"id":[{"id":"10.13039\/501100006588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and objectives: Endothelial dysfunction has been proposed to be an underlying mechanism of the pronounced cardiovascular morbidity in end-stage liver disease (ESLD), but clinical evidence is still limited. In this study, we investigated the association of circulating levels of asymmetric dimethylarginine (ADMA) and nitric oxide (NO) with estimated cardiovascular risk in patients with ESLD awaiting liver transplantation. Materials and Methods: ADMA and NO levels were measured in the sera of 160 adult ESLD patients. The severity of hepatic dysfunction was assessed by the model for end-stage liver disease (MELD) score. The cardiovascular risk was estimated with the European Society of Cardiology Systematic Coronary Risk Estimation (SCORE) index, which was used to dichotomize patients in the subgroups depicting higher and lower cardiovascular risk. Results: Severe hepatic dysfunction (MELD \u2265 18) was present in 38% of the patients, and a higher cardiovascular risk was present in almost half of the patients (N = 74). ADMA and NO both significantly increased with the progression of liver disease and were independently associated with higher cardiovascular risk. Fasting glucose also independently predicted a higher cardiovascular risk, while HDL cholesterol and the absence of concomitant hepatocellular carcinoma were protective factors. Conclusions: These results suggest a remarkable contribution of the deranged arginine\/NO pathway to cardiovascular risk in patients with end-stage liver disease.<\/jats:p>","DOI":"10.3390\/medicina56110622","type":"journal-article","created":{"date-parts":[[2020,11,18]],"date-time":"2020-11-18T09:59:47Z","timestamp":1605693587000},"page":"622","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Association of Asymmetric Dimethylarginine and Nitric Oxide with Cardiovascular Risk in Patients with End-Stage Liver Disease"],"prefix":"10.3390","volume":"56","author":[{"given":"Maro","family":"Dragi\u010devi\u0107","sequence":"first","affiliation":[{"name":"Department of Cardiology, Merkur University Hospital, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iva","family":"Ko\u0161uta","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University Hospital Centre, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egon","family":"Kruezi","sequence":"additional","affiliation":[{"name":"Department of Gynaecology and Obstetrics, Sisters of Charity University Hospital Centre, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7365-0627","authenticated-orcid":false,"given":"Marijana Vu\u010di\u0107","family":"Lovren\u010di\u0107","sequence":"additional","affiliation":[{"name":"Department of Clinical Chemistry and Laboratory Medicie, Merkur University Hospital, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mrzljak","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Merkur University Hospital, 10000 Zagreb, Croatia"},{"name":"School of Medicine, University of Zagreb, 10000 Zagreb, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,11,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/nrgastro.2013.88","article-title":"Liver transplantation: Past, present and future","volume":"10","author":"Zarrinpar","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2011.03.026","article-title":"Cardiovascular Risk Assessment of the Liver Transplant Candidate","volume":"58","author":"Raval","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jacc.2012.05.008","article-title":"Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates: A Scientific Statement From the American Heart Association and the American College of Cardiology Foundation","volume":"60","author":"Lentine","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"9466","DOI":"10.3748\/wjg.v21.i32.9466","article-title":"Asymmetric dimethylarginine as a mediator of vascular dysfunction in cirrhosis","volume":"21","author":"Lluch","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1161\/ATVBAHA.113.300156","article-title":"Smoking and Cardiovascular Disease: Mechanisms of Endothelial Dysfunction and Early Atherogenesis","volume":"34","author":"Messner","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/10715769900301161","article-title":"Endogenous nitric oxide synthesis: Biological functions and pathophysiology","volume":"31","author":"Bredt","year":"1999","journal-title":"Free Radic. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4161\/cam.2.3.6819","article-title":"The DDAH\/ADMA pathway is a critical regulator of NO signaling in vascular homeostasis","volume":"2","author":"Fiedler","year":"2008","journal-title":"Cell Adhes. Migr."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1475-2840-8-27","article-title":"A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria","volume":"8","author":"Sibal","year":"2009","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1161\/CIRCULATIONAHA.108.838268","article-title":"Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community","volume":"119","author":"Sullivan","year":"2009","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jhep.2014.08.024","article-title":"Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension","volume":"62","author":"Mookerjee","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3748\/wjg.v19.i11.1707","article-title":"Current concepts on the role of nitric oxide in portal hypertension","volume":"19","author":"Hu","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1054\/clnu.2002.0614","article-title":"The asymmetrical dimethylarginine (ADMA)-multiple organ failure hypothesis","volume":"22","author":"Nijveldt","year":"2003","journal-title":"Clin. Nutr."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s11064-016-2111-x","article-title":"Asymmetric Dimethylarginine and Hepatic Encephalopathy: Cause, Effect, or Association?","volume":"42","author":"Czarnecka","year":"2017","journal-title":"Neurochem. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7214","DOI":"10.3748\/wjg.14.7214","article-title":"Transjugular intrahepatic portosystemic shunt-placement increases arginine\/asymmetric dimethylarginine ratio in cirrhotic patients","volume":"14","author":"Siroen","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/lt.20286","article-title":"The transplanted liver graft is capable of clearing asymmetric dimethylarginine","volume":"10","author":"Siroen","year":"2004","journal-title":"Liver Transpl."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.20452\/pamw.1355","article-title":"Diagnostic value of plasma asymmetric and symmetric dimethylarginine levels in liver transplant recipients","volume":"122","author":"Wnuk","year":"2012","journal-title":"Pol. Arch. Med. Wewn."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.tips.2015.05.001","article-title":"Nitric oxide in liver diseases","volume":"36","author":"Iwakiri","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","article-title":"European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"33","author":"Perk","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace","year":"2004","journal-title":"Diabetes Care"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/hep.21563","article-title":"Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD)","volume":"45","author":"Kamath","year":"2007","journal-title":"Hepatology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1097\/MPA.0000000000000516","article-title":"Association of Asymmetric Dimethylarginine With Acute Pancreatitis\u2013Induced Hyperglycemia","volume":"45","author":"Trgo","year":"2016","journal-title":"Pancreas"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ajg.2012.362","article-title":"Cardiovascular Risk Factors and Systemic Endothelial Function in Patients with Cirrhosis","volume":"108","author":"Berzigotti","year":"2013","journal-title":"Am. J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e001833","DOI":"10.1161\/JAHA.115.001833","article-title":"Asymmetric dimethylarginine and cardiovascular risk: Systematic review and meta-analysis of 22 prospective studies","volume":"4","author":"Willeit","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.3390\/ijms15033989","article-title":"Increased Circulatory Asymmetric Dimethylarginine and Multiple Organ Failure: Bile Duct Ligation in Rat as a Model","volume":"15","author":"Sheen","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jhep.2004.03.016","article-title":"Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis","volume":"41","author":"Lluch","year":"2004","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.metabol.2010.07.027","article-title":"Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"60","author":"Kasumov","year":"2011","journal-title":"Metabolism"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/JIM.0000000000000230","article-title":"Increased Plasma Levels of Asymmetric Dimethylarginine in Nonalcoholic Fatty Liver Disease","volume":"63","author":"Boga","year":"2015","journal-title":"J. Investig. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3343\/alm.2018.38.5.446","article-title":"Asymmetrical Dimethylarginine Levels in Hepatitis B Virus-Positive Patients","volume":"38","author":"Karakecili","year":"2018","journal-title":"Ann. Lab. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/00365520802400917","article-title":"Unchanged plasma levels of dimethylarginines and nitric oxide in chronic hepatitis C","volume":"44","author":"Lluch","year":"2009","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_32","first-page":"62","article-title":"Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis","volume":"46","author":"Lluch","year":"2007","journal-title":"Hepatology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/liv.13589","article-title":"The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis","volume":"38","author":"Bendtsen","year":"2018","journal-title":"Liver Int."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/j.1478-3231.2011.02579.x","article-title":"Endothelial dysfunction in the regulation of cirrhosis and portal hypertension","volume":"32","author":"Iwakiri","year":"2012","journal-title":"Liver Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1055\/s-2002-35413","article-title":"Elevated Nitric Oxide Levels in Patients with Chronic Liver Disease and Cirrhosis Correlate with Disease Stage and Parameters of Hyperdynamic Circulation","volume":"40","author":"Arkenau","year":"2002","journal-title":"Z. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1136\/gut.44.5.749","article-title":"Hepatic and splanchnic nitric oxide activity in patients with cirrhosis","volume":"44","author":"Sarela","year":"1999","journal-title":"Gut"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.3748\/wjg.v13.i3.421","article-title":"Serum levels of soluble Fas, nitric oxide and cytokines in acute decompensated cirrhotic patients","volume":"13","author":"Elsing","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0016-5085(00)70180-6","article-title":"Contribution of nitric oxide to the pathogenesis of cirrhotic cardiomyopathy in bile duct\u2013ligated rats","volume":"118","author":"Liu","year":"2002","journal-title":"Gastroenterology"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12933-018-0762-4","article-title":"Association between insulin resistance and the development of cardiovascular disease","volume":"17","author":"Ormazabal","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"240","DOI":"10.7150\/ijms.17738","article-title":"Interrelationship between insulin resistance and portal haemodynamic abnormality in cirrhosis","volume":"14","author":"Maruyama","year":"2017","journal-title":"Int. J. Med. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10238-013-0262-5","article-title":"The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins","volume":"14","author":"Chrostek","year":"2014","journal-title":"Clin. Exp. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.amjmed.2017.02.024","article-title":"Associated Risk of Malignancy in Patients with Cardiovascular Disease: Evidence and Possible Mechanism","volume":"130","author":"Hasin","year":"2017","journal-title":"Am. J. Med."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/56\/11\/622\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:33:59Z","timestamp":1760178839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/56\/11\/622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,18]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["medicina56110622"],"URL":"https:\/\/doi.org\/10.3390\/medicina56110622","relation":{},"ISSN":["1648-9144"],"issn-type":[{"type":"electronic","value":"1648-9144"}],"subject":[],"published":{"date-parts":[[2020,11,18]]}}}